Arbutus Biopharma (NASDAQ:ABUS) Releases Earnings Results

Arbutus Biopharma (NASDAQ:ABUS) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01), Zacks reports. The firm had revenue of $1.73 million during the quarter, compared to analyst estimates of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 68.02%. During the same quarter in the previous year, the business posted ($0.10) earnings per share.

Arbutus Biopharma Trading Down 2.0 %

ABUS stock opened at $3.74 on Friday. The firm has a 50 day moving average of $3.39 and a 200-day moving average of $2.97. The company has a market cap of $704.87 million, a price-to-earnings ratio of -8.49 and a beta of 1.96. Arbutus Biopharma has a 12-month low of $1.69 and a 12-month high of $3.98.

Wall Street Analyst Weigh In

ABUS has been the topic of a number of research analyst reports. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, June 5th. JMP Securities lifted their price target on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research note on Thursday, June 6th. Finally, StockNews.com lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Friday.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.